Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Use of hla-a*02:01 and hla-c*01:02 in drug eruption caused by tanshinone

A technology of HLA-A and HLA-C, which is applied in the direction of biochemical equipment and methods, and the determination/testing of microorganisms, can solve the problem of no reliable means of predicting drug eruption

Active Publication Date: 2021-12-07
AFFILIATED HUSN HOSPITAL OF FUDAN UNIV +1
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] There is still no reliable means of predicting drug eruption caused by tanshinone

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of hla-a*02:01 and hla-c*01:02 in drug eruption caused by tanshinone
  • Use of hla-a*02:01 and hla-c*01:02 in drug eruption caused by tanshinone
  • Use of hla-a*02:01 and hla-c*01:02 in drug eruption caused by tanshinone

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0028] Example 1, HLA-A*02:01 and / or HLA-C*01:02 alleles are genetic markers of risk of drug eruption caused by tanshinone

[0029] 1. Sample

[0030] The samples were human peripheral blood, including case samples, tanshinone-resistant samples and healthy control samples.

[0031] 1. Drug eruption group caused by tanshinone

[0032] 18 patients with drug eruption caused by tanshinone; the average age of the patients was 30.61±14.57 years old, the ratio of male to female was 8:1; the incubation period of tanshinone was 8.83±2.64 days (3-14 days).

[0033] The clinical manifestations of patients were mostly exanthematous drug eruption (17 / 18), manifested as erythema multiforme-like rash diffusely distributed all over the body, and some patients may be accompanied by systemic damage such as fever and abnormal liver function. Only one patient was diagnosed with Stevens-Johnson syndrome (1 / 18) because of oral and conjunctival mucosal damage accompanied by abnormal liver function...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses the use of HLA-A*02:01 and HLA-C*01:02 in drug eruption caused by tanshinone. The invention provides the application of a substance for detecting whether a human has an HLA-A*02:01 allele in the preparation of a product for detecting or evaluating the risk of adverse drug reactions in response to tanshinone in humans. The experiment of the present invention proves that human leukocyte antigen gene—HLA-A*02:01 and / or HLA-C*01:02 allele is related to the onset of drug eruption caused by tanshinone. HLA‑A*02:01 and / or HLA‑C*01:02 alleles can be used as marker genes to predict tanshinone-induced drug eruption.

Description

technical field [0001] The invention belongs to the field of biotechnology, and in particular relates to the application of HLA-A*02:01 and HLA-C*01:02 in drug eruption caused by tanshinone. Background technique [0002] Drug eruption refers to the adverse reactions of the skin and (or) mucous membranes caused by drugs entering the human body through various channels. It is the most common adverse drug reaction, with a reported incidence of 1-3% in the past. With the increasing incidence of drug eruption in my country year by year, it not only causes serious harm to personal health and economic loss, but also becomes an obstacle in public health that hinders the safety of clinical medication and the development of new drugs, and has become a research hotspot at home and abroad. Recent studies at home and abroad have revealed that the occurrence of drug eruptions caused by various drugs is related to the coding genes of individual human leukocyte antigens (HLA), and HLA allel...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C12Q1/6883
CPCC12Q1/6883C12Q2600/106C12Q2600/136C12Q2600/156
Inventor 骆肖群邢清和朱沁媛徐金华陈圣安杨凡萍熊浩
Owner AFFILIATED HUSN HOSPITAL OF FUDAN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com